Literature DB >> 29675694

[Principles of PET].

B Beuthien-Baumann1.   

Abstract

Positron emission tomography (PET) is a procedure in nuclear medicine, which is applied predominantly in oncological diagnostics. In the form of modern hybrid machines, such as PET computed tomography (PET/CT) and PET magnetic resonance imaging (PET/MRI) it has found wide acceptance and availability. The PET procedure is more than just another imaging technique, but a functional method with the capability for quantification in addition to the distribution pattern of the radiopharmaceutical, the results of which are used for therapeutic decisions. A profound knowledge of the principles of PET including the correct indications, patient preparation, and possible artifacts is mandatory for the correct interpretation of PET results.

Entities:  

Keywords:  Attenuation correction; Coincidence detection; Hybrid PET; Positron emission tomography; Standardized uptake value (SUV)

Mesh:

Substances:

Year:  2018        PMID: 29675694     DOI: 10.1007/s00117-018-0380-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  20 in total

1.  Radiation doses for pediatric nuclear medicine studies: comparing the North American consensus guidelines and the pediatric dosage card of the European Association of Nuclear Medicine.

Authors:  Frederick D Grant; Michael J Gelfand; Laura A Drubach; S Ted Treves; Frederic H Fahey
Journal:  Pediatr Radiol       Date:  2014-11-01

2.  Radiation exposure should not limit bone scintigraphy with 18F-NaF.

Authors:  Robert Freudenberg; Liane Oehme; Joerg Kotzerke
Journal:  J Nucl Med       Date:  2012-09-06       Impact factor: 10.057

3.  Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials.

Authors:  Frank Hofheinz; Ivayla Apostolova; Liane Oehme; Jörg Kotzerke; Jörg van den Hoff
Journal:  J Nucl Med       Date:  2017-05-04       Impact factor: 10.057

Review 4.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.

Authors:  Ali Afshar-Oromieh; John W Babich; Clemens Kratochwil; Frederik L Giesel; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

5.  18F-FDG PET-CT scanning and diabetic patients: what to do?

Authors:  Jon Martin; Nayyar Saleem
Journal:  Nucl Med Commun       Date:  2014-12       Impact factor: 1.690

6.  Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.

Authors:  Joo Hyun O; Brandon S Luber; Jeffrey P Leal; Hao Wang; Vanessa Bolejack; Scott M Schuetze; Lawrence H Schwartz; Lee J Helman; Denise Reinke; Laurence H Baker; Richard L Wahl
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

7.  Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG.

Authors:  S Leide-Svegborn
Journal:  Radiat Prot Dosimetry       Date:  2010-02-18       Impact factor: 0.972

8.  Correction of scan time dependence of standard uptake values in oncological PET.

Authors:  Jörg van den Hoff; Alexandr Lougovski; Georg Schramm; Jens Maus; Liane Oehme; Jan Petr; Bettina Beuthien-Baumann; Jörg Kotzerke; Frank Hofheinz
Journal:  EJNMMI Res       Date:  2014-04-03       Impact factor: 3.138

9.  The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG.

Authors:  Jörg van den Hoff; Liane Oehme; Georg Schramm; Jens Maus; Alexandr Lougovski; Jan Petr; Bettina Beuthien-Baumann; Frank Hofheinz
Journal:  EJNMMI Res       Date:  2013-11-23       Impact factor: 3.138

10.  An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET.

Authors:  Frank Hofheinz; Rebecca Bütof; Ivayla Apostolova; Klaus Zöphel; Ingo G Steffen; Holger Amthauer; Jörg Kotzerke; Michael Baumann; Jörg van den Hoff
Journal:  EJNMMI Res       Date:  2016-03-02       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.